Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Predicting the need for biopsy to detect clinically significant prostate cancer in patients with a magnetic resonance imaging–detected prostate imaging reporting and data system/Likert ≥3 Lesion: Development and multinational external validation of the imperial rapid access to prostate imaging and diagnosis risk score
Local failure events in prostate cancer treated with radiotherapy: A pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN)
Prostate-specific membrane antigen radioguided surgery to detect nodal metastases in primary prostate cancer patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection: Results of a planned interim analysis of a prospective phase 2 study
Not all adverse pathology features are equal: Identifying optimal candidates for adjuvant radiotherapy among patients with adverse pathology at radical prostatectomy
Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: A phase II randomized controlled trial